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Cost and utility analysisSelf-guided internet-delivered cognitive behavior therapy (iCBT) has considerable public health potential for
treating anxiety and depression. However, no research has examined the use of self-guided iCBT, that is, treat-
ment without contact with a clinician, speciﬁcally for older adults. The aim of the present studywas to undertake
a preliminary examination of the acceptability, efﬁcacy and health economic impact of two entirely self-guided
iCBT programs for adults over 60 years of age with anxiety and depression. Two separate single-group feasibility
open trials of self-guided iCBT were conducted, the Anxiety Trial (n = 27) and the Depression Trial (n = 20),
using the control groups of two randomized controlled trials. The online treatment packages consisted of ﬁve
online educational lessons, whichwere delivered over 8weekswithout clinical contact. Participants rated the in-
terventions as acceptable with more than 90% reporting the course was worth their time and more than 70% of
participants completing at least 3 of the 5 lessons within the eight weeks. Signiﬁcant reductions on measures of
anxiety (Generalized Anxiety Disorder 7-item; GAD-7) and depression (Patient Health Questionnaire 9-item;
PHQ-9) were observed from pre-treatment to post-treatment in both the Anxiety Trial (GAD-7 Cohen's d =
1.17; 95% CI: 0.55 to 1.75) and the Depression Trial (PHQ-9 Cohen's d=1.06; 95% CI: 0.33 to 1.73). The economic
analyses indicated that there was statistically signiﬁcant improvement in health-related quality of life compared
to baseline and marginally higher costs associated with treatment for both the Anxiety Trial ($69.84; 95% CI:
$4.24 to $135.45) and the Depression Trial ($54.98; 95% CI: $3.84 to $106.12). The results provide preliminary
support for the potential of entirely self-guided iCBT for older adults with anxiety and depression and indicate
larger scale and controlled research trials are warranted.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Epidemiological surveys indicate that the rates of anxiety and de-
pression tend to be lower in older adults. However, these surveys also
indicate that approximately 8% and 3% of adults over 65 years of age
still meet formal diagnostic criteria for depression and anxiety
disorders, respectively (Byers et al., 2010; Gum et al., 2009; Pirkis
et al., 2009). This is signiﬁcant given that the number of adults over 65
is projected to increase in the coming decades and given thesend Clinical Trials Registry:
ent of Psychology, Macquarie
9979; fax: +61 2 9850 8062.
. This is an open access article underconditions compound the effects of physical comorbidities (Katon
et al., 2007; Braam et al., 2005).
There is considerable evidence for the efﬁcacy of psychological treat-
ments, such as cognitive behavior therapy (CBT), for older adults with
anxiety and depression (Scogin et al., 2005; Nordhus and Pallesen,
2003; Ayers et al., 2007; Gould et al., 2012;Wetherell et al., 2005). How-
ever, research indicates that the proportion of older adults seeking and
receiving evidence-based treatment for anxiety and depression is low
(Australian Bureau of Statistics, 2007; Troller et al., 2007). This has led
several researchers to examine internet-delivered cognitive behavior
therapy (iCBT) for older adults (i.e., 60 years and older) with anxiety
and depression as a way of overcoming barriers to traditional face-to-
face treatments and increasing access to evidence-based treatment
(Dear et al., 2013; Spek et al., 2007; Zou et al., 2012; Dear et al., in
press; Titov et al., in press). For example, two recent randomizedthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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signiﬁcant improvements in symptoms of anxiety and depression
(Cohen's ds N 1.0) among adults over the age of 60 compared with a
Waitlist-Control Group (Dear et al., in press; Titov et al., in press).
Moreover, these trials found the improvements in symptoms to be
maintained at a 12-month follow-up and found the interventions to
be cost-effective at common willingness-to-pay thresholds.
There is now strong meta-analytic evidence for iCBT treatments for
anxiety and depression in adults generally (Andersson and Cuijpers,
2009; Andrews et al., 2010; Cuijpers et al., 2009). Importantly, the ﬁnd-
ings of these meta-analyses have suggested that iCBT treatments pro-
vided with weekly clinician-guidance may achieve better clinical
outcomes than iCBT provided in self-guided formats, that is, where no
regular contact with a clinician is provided (Andersson and Cuijpers,
2009; Cuijpers et al., 2009). However, since thesemeta-analyses, several
clinical trials have produced clinical results that are more encouraging
of self-guided iCBT treatments (Berger et al., 2011; Furmark et al.,
2009; Leykina et al., in press). For example, one study found no differ-
ences in clinical outcomes between self-guided and clinician-guided
iCBT for adults with depression (Berger et al., 2011) and another
found no differences for adults with social anxiety disorder (Furmark
et al., 2009). Another trial (n = 257) examined self-guided iCBT for
symptoms of anxiety and depression and found large clinical effects
(Cohen's ds N .80) consistent with those obtained in clinician-guided
treatments, particularly among participants with comorbid anxiety
and depression and where automatic emails were provided (Titov
et al., 2013, 2014). Thesemore recent studies are encouraging and high-
light the public health potential of well-developed self-guided treat-
ments for anxiety and depression (Andersson and Titov, 2014; Titov,
Dear & Andersson, 2014). Unfortunately, despite their potential, no
studies have examined the use of self-guided iCBT for anxiety and
depression among older adults to date.
The present study sought to explore the efﬁcacy, acceptability and
health economic impact of self-guided iCBT for older adultswith anxiety
and depression using two separate single group open trials. To do this,
the present study employed the Waitlist Control-Groups from two
previous randomized controlled trials (RCTs; Dear et al., in press; Titov
et al., in press), where the control groups were provided with self-
guided iCBT. It was hypothesized that: (1) participants would report
signiﬁcantly reduced symptoms of anxiety and depression at post-
treatment, (2) these reductions in symptoms would be maintained at
3-month follow-up, and (3) the self-guided iCBT treatment would
reduce costs and improve health-related quality of life.
2. Method
2.1. Design
The present study reports the pre-treatment to post-treatment and
3-month follow-up data of two delayed-treatment Waitlist Control
Groups from two previous RCTs examining iCBT treatments for older
adults with symptoms of anxiety (Dear et al., in press) and depression
(Titov et al., in press), respectively. These Waitlist Control Groups
were provided access to the iCBT treatment programs after the Treat-
ment Groups had completed treatment. However, rather than receiving
weekly contact with a Clinical Psychologist, participants in the Waitlist
Control Groups were provided access to the iCBT treatment programs
in an entirely self-guided format; that is, without contact with a Clinical
Psychologist.
2.2. Participants
Interested older adults applied online to participate in the initial
RCTs via an established website (www.ecentreclinic.org) after reading
details about the studies. Sixty-two participants were allocated to the
Waitlist-Control Groups from the two initial RCTs; forming the AnxietyGroupopen trial and theDepressionGroup open trial reported here. The
inclusion criteria were: (i) resident of Australia; (ii) at least 60 years of
age; (iii) have been assessed by a GP or specialist to rule out obvious
physical causes for their symptoms. An initial additional criterion was
that applicants have a total score ≥10 on the Patient Health
Questionnaire-9 Item (PHQ-9; Kroenke et al., 2001) or ≥8 on the
Generalized Anxiety Disorder-7 Item Scale (GAD-7; Spitzer et al.,
2006). However, this criterion was later removed due to the consider-
able number of applicants who did not meet this criterion in the initial
RCTs. No formal criteria for symptoms were required thereafter;
however, all participants had to self-report difﬁculties with anxiety or
depression and want to participate in treatment. The exclusion criteria
were: (i) currently participating in CBT; (ii) using illicit drugs or con-
suming more than three standard drinks/day; (iii) diagnosed with
schizophrenia or bi-polar disorder; (iv) experiencing severe symptoms
of depression (deﬁned as a total score N19 or responding N2 toQuestion
9 (suicidal ideation) on the PHQ-9); and (v) if taking medication for
anxiety or depression, not being on a stable dose of medication for at
least one month. Details of participant ﬂow are shown in Fig. 1.
Fifty-four of the 62 participants from the Waitlist Control Groups of
the initial RCTs completed the pre-treatment questionnaires and were
eligible to participate in the present study. The demographic character-
istics and diagnostic composition of the sample are shown in Table 1.
The study was approved by the Human Research Ethics Committee
(HREC) of Macquarie University, Sydney, Australia and the trials were
registered on the Australian and New Zealand Clinical Trials Registry
(ANZCTR) as ACTRN12611000929909 and ACTRN12611000927921.2.3. Measures
2.3.1. Patient Health Questionnaire-9 Item (PHQ-9; Kroenke et al., 2001)
The PHQ-9 comprises 9 items measuring symptoms of major de-
pressive disorder based on the DSM-IV criteria for depression. A total
score of 10 on the PHQ-9 has been identiﬁed as an important threshold
for identifying DSM-IV congruent depression, with increasing scores in-
dicating greater symptom severity (Kroenke et al., 2001). The PHQ-9
has good internal consistency (Titov et al., 2011) and is sensitive to
change (Kroenke et al., 2010). The psychometric properties of the
PHQ-9 have been examined and found to be satisfactory in older adults
(Phelan et al., 2010).2.3.2. Generalized Anxiety Disorder 7-Item Scale (GAD-7; Spitzer et al.,
2006)
The GAD-7 is a 7-item measure sensitive to the symptoms of GAD,
social phobia and panic disorderwith increasing scores indicating great-
er severity of symptoms. The GAD-7 has good internal consistency (α=
.79–.91) and good convergent and divergent validity with other anxiety
and disability scales (Spitzer et al., 2006; Dear et al., 2011). A total score
of 8 on theGAD-7 has been shown to be the optimumsensitive and spe-
ciﬁc threshold for the possible presence of an anxiety disorder (Kroenke
et al., 2007). One recent study has found the GAD-7 to be sensitive to
symptoms of GAD among older adults; however, the lower cut-off
score of 5 is recommended (Wild et al., in press).2.3.3. Mini International Neuropsychiatric Interview Version 5.0.0 (MINI;
Sheehan et al., 1998)
The MINI is a brief diagnostic interview developed to determine the
presence of current Axis-I disorders using DSM-IV diagnostic criteria. It
has excellent inter-rater reliability (k = 0.88–1.00) and adequate con-
current validity with the Composite International Diagnostic Interview
(CIDI; World Health Organization, 1990). The MINI was administered
in the present trials by two trained and experienced Clinical Psycholo-
gists (JBZ & CNL) under the supervision of two Senior Clinical Psycholo-
gists (BFD & NT).
Fig. 1. Participant ﬂow chart for the two single-group open trials.
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The EQ-5D-5L is a standard and widely used measure of health-
related quality of life (Brazier, 2007; Herdman et al., 2011). It comprises
5 items,which enquire about 5 dimensions of health:mobility, self-care,
usual activities, pain and discomfort, and anxiety and depression. Re-
sponses to the ﬁve dimensions are weighted and summed to create a
total score between 0 (i.e., indicating deceased) and 1 (i.e., indicating
full-health). The EQ-5D-5L has been shown to have good convergent va-
lidity with the World Health Organization 5-itemWell Being question-
naire (Janssen et al., 2013). EQ-5D-5L scores were converted into utility
values using an algorithm for the Australian population (Norman et al.,
2013). Then quality-adjusted life years (QALYs) were calculated using
the time-weighted average of the utility scores (Glick, 2007).2.4. Interventions
Participants were provided access to theManaging Stress and Anxiety
Course (n = 32) or theManaging Your Mood Course (n = 22) based on
their principal symptoms reported during assessment. These interven-
tions are described in detail elsewhere (Dear et al., in press; Titov
et al., in press), but both are structured online interventions, which
encourage participants to learn and practice core CBT psychological
skills. Participants complete these interventions over an 8 week period
and both interventions are comprised of 5 online lessons, 5 lesson
summaries and homework assignments, regular automatic emails and
several detailed case-studies, which participants follow through the
Course. Both Courses follow the same structure, where lessons 1, 2, 3,
4, and 5 are available at the beginning of weeks 1, 2, 4, 5, and 7, respec-
tively. Both Courses also introduce and teach the same core skills, exceptthat one focuses on the application of the skills to manage anxiety and
the other focuses on the application of the skills to manage depression.
These courses provide age-appropriate case stories and examples of
skill use; however, the presentation of therapeutic information and
the teaching of the psychological skills was notmodiﬁed and is identical
to the general iCBT courses theywere based on (see Dear et al., in press;
Titov et al., in press). All material is presented in both a didactic form
(i.e., text based instructions and information) and a case-enhanced
learning form (i.e., where educational stories are used to demonstrate
the application of skills and problem resolution). Based on previous re-
search supportive of the importance of automatic emails (Titov et al.,
2013; Titov et al., 2014), both interventions were provided with auto-
matic emails, which notiﬁed participants of new material, prompted
participants to view unread materials, encouraged progress through
the programs and normalized the difﬁculties in learning new skills
and managing symptoms.
2.5. Statistical analyses
2.5.1. Clinical analyses
All analyseswere conducted using SPSS version 22. Participantswho
did not start treatment were not included in any analyses. Mixed-
models analyses, employing an autoregressive covariance structure,
maximum likelihood estimation and pre-treatment scores as a
covariate, were used to analyze changes on the symptom measures.
These mixed models analyses were run separately for the overall
samples and for the clinical subsamples; deﬁned as those participants
scoring ≥10 on the PHQ-9 or ≥8 on the GAD-7 at pre-treatment. The
mixed-models approach is consistent with intention-to-treat analytic
approaches under the assumption that data is missing at random. Effect
Table 1
Demographic characteristics of participants in the anxiety and depression trials.
Variable Anxiety Trial
(n = 27)
Depression
Trial
(n = 20)
n % n %
Gender
Male 14 51.9% 6 30.0%
Female 13 48.1% 14 70.0%
Age
Mean 65.3 (5.33) 66.6 (3.71)
Range 60 to 81 62 to 76
Marital status
Single/never married 2 7.4% 4 20.0%
Married/de facto 20 74.1% 6 30.0%
Separated/divorced/widowed 5 18.5% 10 50.0%
Education
None 4 14.8% 2 10.0%
High school 5 18.5% 8 40.0%
Trade/technical certiﬁcate 3 11.1% 2 10.0%
Diploma/degree 15 55.6% 8 40.0%
Employment status
Full time 5 18.5% 0 0.0%
Part time/student 8 29.6% 2 10.0%
Unemployed, retired or disabled 14 51.9% 18 90.0%
Previous mental health treatment 14 51.9% 11 55.0%
Taking medication for mental health
condition
9 33.3% 9 45.0%
Diagnostic data
MINI-diagnosis at assessment
Generalized Anxiety Disorder 17 62% 6 30%
Panic disorder 8 29% 1 5%
Social anxiety disorder 9 33% 4 20%
Major depressive episode 16 59% 17 85%
Number of diagnoses
0 3 11% 3 15%
1 9 33% 11 55%
2 4 14% 1 5%
≥3 11 40% 5 25%
MINI; Mini International Neuropsychiatric Interview.
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within-group effects based on the observed means.
The following criteria of clinical signiﬁcance were used. First, reliable
improvementwas calculated using standard procedures for determining
reliable change (Jacobson & Truax, 1991), which take into account the
reliability and measurement error associated with the questionnaire
being employed. Speciﬁcally, a participant was deemed to have made
a reliable improvement if they scored above the total cut-off at pre-
treatment (i.e., ≥8 on the GAD-7 or ≥10 on the PHQ-9) and their
symptoms improved by a reliable amount; that is, more than 5.20 or
3.53 on the PHQ-9 and the GAD-7, respectively (Gyani et al., 2013). Sec-
ond, reliable recovery was determined to have occurred if a participant
scored above the clinical cut-off at pre-treatment, made a reliable im-
provement, and scored below the clinical cut-off at the post-treatment
or follow-up time point of interest (Gyani et al., 2013). Importantly,
these analyses were calculated separately for the PHQ-9 and the GAD-
7 and for each trial with baseline observations being carried forward
as a conservative approach for controlling for missing data.
2.5.2. Economic analysis
The economic analysis was conducted from the perspective of the
national health provider in Australia. Data on health-related resource
use and health-related quality of life (HRQoL) was collected at baseline,
week 8 (i.e. end of treatment) and 3-months post-treatment. Individual
patient-level costswere calculated as the product of healthcare resource
use and relevant unit costs for: (1) primary and secondary health care
consultations and admissions, (2) use of anti-depressant and anxiolytic
medications, and (3) resource use associated with the iCBT treatmentprovided. Resource use was valued using costs from the Medicare Ben-
eﬁts Schedule (Australian Government Department of Health and Age-
ing, 2013) and the Pharmaceutical Beneﬁts Scheme (Australian
Government Department of Health, 2013). Patient-level HRQoL was
measured using the EuroQol EQ-5D-5L questionnaire (Herdman et al.,
2011; Brazier, 2007). EQ-5D scores were converted into utility values
using a valuation algorithm for the Australian population (Norman
et al., 2013).
Changes in costs and health effects (measured in terms of HRQoL)
were estimated as the difference between post-treatment time points
(i.e., 8 weeks and 3 months, respectively) and pre-treatment values
and then summarized for each treatment arm. Difference in costs and
beneﬁts was tested using paired t-tests for each group using 10,000
bootstrapped samples.3. Results
3.1. Treatment satisfaction
Of the participants providing feedback about the course in the Anx-
iety Trial (n = 22), 20/22 (90%) indicated that they were very satisﬁed
or mostly satisﬁed with the Course, 22/22 (100%) indicated that it was
worth their time and 21/22 (95%) indicated that they would recom-
mend the course to a friend. Similarly, of the participants providing
feedback about the course in the Depression Trial (n = 14), 11/14
(78%) indicated that they were very satisﬁed or mostly satisﬁed with
the Course, 13/14 (92%) indicated that it was worth their time and
14/14 (100%) indicated that they would recommend the course to a
friend.3.2. Symptom outcomes for overall samples
Means, standard deviations and effect sizes for the overall sam-
ples are shown in Table 2. For the Anxiety Trial, the mixed-models
analyses revealed signiﬁcant effects for Time on the GAD-7
(F2, 43 = 15.70, p b .001) and PHQ-9 (F2, 43= 20.50, p b .001). Pairwise
comparisons revealed that, on both measures, scores reduced signiﬁ-
cantly from pre-treatment to post-treatment (p b .001), but not from
post-treatment to 3-month follow-up (p range: .166 to .342).
Similarly, for the Depression Trial, mixed-models analyses revealed
signiﬁcant effects for Time on the PHQ-9 (F2, 31 = 12.90, p b .001) and
GAD-7 (F2, 30 = 3.76, p = .034). Pairwise comparisons revealed that
scores reduced signiﬁcantly from pre-treatment to post-treatment on
the PHQ-9 and GAD-7 (p range: b .001 to .031), but not from post-
treatment to 3-month follow-up (p range: .841 to .918).3.3. Symptom outcomes for clinical subsamples
Means, standard deviations and effect sizes for the clinical subsam-
ples are shown in Table 2. For the Anxiety Trial, the mixed-models
analyses revealed signiﬁcant effects for Time on the GAD-7 (F2, 24 =
11.01, p b .001) and PHQ-9 (F2, 22=24.63, p b .001) for the clinical sub-
samples on each measure. Pairwise comparisons revealed that, on both
measures, scores reduced signiﬁcantly from pre-treatment to post-
treatment (p b .001), but not from post-treatment to 3-month follow-
up (p range: .271 to .335).
Similarly, for the Depression Trial, mixed-models analyses revealed
signiﬁcant effects for Time on the PHQ-9 (F2, 24 = 11.01, p b .001) and
GAD-7 (F2, 14 = 21.07, p b .001) for the clinical subsamples on each
measure. Pairwise comparisons revealed that scores reduced
signiﬁcantly from pre-treatment to post-treatment on the PHQ-9 and
GAD-7 (p b .001), but not from post-treatment to 3-month follow-up
(p range: .375 to .985).
Table 2
Means, standard deviations and effect sizes (Cohen's d) for the observed and estimated marginal means for each trial.
n Observed means Estimated means Effect sizes (based on observed means)
Pre Post 3-Month follow-up Pre Post 3-Month follow-up Pre to post Pre to 3-month follow up
Overall sample
Anxiety Trial
GAD-7 27 10.30 (4.94) 5.43 (3.64) 5.76 (3.74) 10.29 (4.15) 5.48 (4.10) 6.27 (3.95) 1.17 (0.55 N 1.75) 0.99 (0.37–1.58)
PHQ-9 27 10.78 (4.89) 4.87 (3.78) 5.76 (4.37) 10.77 (4.31) 4.99 (4.25) 6.18 (4.09) 1.26 (0.64–1.85) 1.00 (0.38–1.58)
Depression Trial
PHQ-9 20 12.40 (5.68) 7.13 (4.95) 6.57 (5.49) 12.40 (5.18) 6.99 (5.04) 7.22 (4.71) 1.06 (0.33–1.73) 1.04 (0.29–1.74)
GAD-7 20 7.25 (4.60) 4.88 (3.76) 4.86 (4.61) 7.25 (4.17) 4.78 (4.04) 4.88 (3.81) 0.60 (−0.08–1.26) 0.59 (−0.12–1.27)
Clinical subsample
GAD-7 ≥ 8
Anxiety Trial 17 13.29 (3.54) 5.86 (3.57) 6.91 (3.59) 13.29 (3.40) 5.85 (3.39) 7.00 (3.22) 2.09 (1.17–2.91) 1.79 (0.86–2.62)
Depression Trial 10 10.80 (3.25) 6.63 (3.88) 6.50 (4.63) 10.80 (3.35) 6.61 (3.16) 5.85 (2.79) 1.18 (0.12–2.12) 1.13 (−0.01–2.15)
PHQ-9 ≥ 10
Anxiety Trial 14 14.93 (2.70) 6.82 (4.04) 8.11 (4.16) 14.29 (3.37) 6.83 (3.34) 8.03 (3.24) 2.42 (1.32–3.36) 2.05 (0.96–2.99)
Depression Trial 15 14.67 (4.54) 8.83 (4.46) 8.30 (5.55) 14.66 (4.53) 8.70 (4.46) 8.67 (4.26) 1.30 (0.43–2.09) 1.28 (0.37–2.11)
Note. GAD-7; Generalized Anxiety Disorder 7-item. PHQ-9; Patient Health Questionnaire 9-item.
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The proportions of participants reporting reliable improvement and
reliable recovery are shown in Table 3. For the Anxiety Trial, 70% of par-
ticipants reported a reliable improvement and more than 47% reported
having made a reliable recovery on the GAD-7 at post-treatment.
Similarly, in the Depression Trial, 40% of participants reported a reliable
improvement and 33% reported a reliable recovery on the PHQ-9 at
post-treatment.3.5. Economic analyses
Themean costs in the Anxiety Trial (including the intervention cost)
were $69.84more per participant over the eightweek treatment period
(95% bias corrected CI: $4.24 to $135.45) compared with the pre-
treatment costs for the same period in the same group (Table 4). How-
ever, at three-month follow-up, there was no statistically signiﬁcant
cost difference compared to the pre-treatment costs. The utility scores
evaluated using the EQ-5D-5L were statistically signiﬁcantly higher at
eight weeks (estimate: 0.125; 95% bias corrected CI: 0.0679 to 0.181)
and at 3-month follow-up (estimate: 0.172; 95% bias corrected CI:
0.096 to 0.247) compared to the baseline. These ﬁndings suggest that
iCBT is associated with higher costs during the treatment period due
to the cost of intervention (and no cost difference during the follow-
up period) and results in higher health-related quality of life, which is
primarily attributable to improvement in the anxiety/depression score
in the EQ-5D-5L questionnaire.Table 3
Proportions reporting reliable improvement and reliable recovery.
Clinical subsample n Post-treatment
Reliable improvement R
GAD-7 (GAD-7 ≥ 8)
Anxiety Trial 17 12/17
(70%)
8
(4
Depression Trial 10 8/10
(80%)
7
(7
PHQ-9 (PHQ-9 ≥ 10)
Anxiety Trial 14 8/14
(57%)
7
(5
Depression Trial 15 6/15
(40%)
5
(3
Note. Baseline observationswere carried forward for missing data. A person was deemed to hav
their symptoms improved by a reliable amount. A person was deemed to have reliably recover
and scored below the clinical cut-off at the post-treatment or follow-up time point of interest. GThe Depression Trial also found higher mean costs per participant
during the treatment period (estimate: $54.98; 95% bias corrected CI:
$3.84 to $106.12) and no signiﬁcant cost difference during the follow-
up period (Table 4). Patient utility scores were not statistically signiﬁ-
cantly different from baseline at the end of treatment (estimate:
0.074; 95% bias corrected CI:−0.064 to 0.211) but were signiﬁcantly
higher at 3-month follow-up (estimate: 0.185; 95% bias corrected CI:
0. 075 to 0.295) compared to the baseline utility score. These ﬁndings
suggest that iCBT is associated with an improvement in health-related
quality of life in depressed older adults at a marginal cost which is in-
curred during the treatment period.4. Discussion
The current study extends previous research and provides a prelim-
inary examination of the acceptability, efﬁcacy and health economic im-
pact of two self-guided iCBT interventions for older adults with anxiety
and depression. It was hypothesized that (1) participants would report
signiﬁcantly reduced symptoms of anxiety and depression at post-
treatment, (2) these reductions in symptoms would be maintained at
3-month follow-up, and (3) the self-guided iCBT treatment would
reduce costs and improve health-related quality of life. These hypothe-
ses were supported. Moderate to large within-group effect sizes were
observed on measures of anxiety and depression in both trials, which
were maintained at 3-month follow-up. Moreover, in both groups,
there were statistically signiﬁcant improvements in health-related
quality of life compared to baseline and there were marginally higher3-Month follow-up
eliable recovery Reliable improvement Reliable recovery
/17
7%)
11/17
(64%)
7/17
(41%)
/10
0%)
8/10
(80%)
7/10
(70%)
/14
0%)
8/14
(57%)
8/14
(50%)
/15
3%)
8/15
(53%)
7/15
(46%)
emade a reliable improvement if they scored above the total cut-off at pre-treatment and
ed if they scored above the clinical cut-off at pre-treatment, made a reliable improvement,
AD-7; Generalized Anxiety Disorder 7-item. PHQ-9; Patient Health Questionnaire 9-item.
Table 4
Change in utility scores and total health care costs at post-treatment and 3-month follow-up (compared to pre-treatment)a.
End of treatment (at 8 weeks) 3-Month follow-up
Difference between end of treatment
and baseline: mean (SE)b
p-Value for relevant
paired t-testb
Difference between 3-month follow-up
and baseline: mean (SE)b
p-Value for relevant
paired t-testb
Anxiety Trial
Utility score (based on EQ-5D) 0.125 (0.029) p = 0.000 0.172 (0.038) p = 0.000
Total costc 69.84 (33.47) p = 0.037 2.12 (17.16) p = 0.902
Depression Trial
Utility score (based on EQ-5D) 0.074 (0.07) p = 0.29 0.185 (0.056) p = 0.001
Total costc 54.98 (26.09) p = 0.035 14.08 (49.47) p = 0.776
a Note that the resource use questionnaire recorded consultations and admissions in the last eight weeks. For the post-treatment analysis (at 8 weeks), the cost of intervention is also
added.
b Based on 10,000 bootstrapped samples.
c Including health service resource costs (and intervention cost included in the post-treatment and 3-month follow-up costs).
22 B.F. Dear et al. / Internet Interventions 2 (2015) 17–23costs incurredduring the treatment period.However, the cost of provid-
ing treatment was relatively low.
The results of the present study are encouraging regarding the po-
tential of self-guided iCBT interventions for older adults with anxiety
and depression. The results are broadly consistent, in terms of clinical
efﬁcacy, with recent trials examining clinician-guided iCBT interven-
tions for older adults with symptoms of anxiety and depression (Dear
et al., in press; Titov et al., in press), which found similarly large
within-group effect sizes (Cohen's d N 1.0) from pre-treatment to
post-treatment and large effect size differences (Cohen's d N 1.0) be-
tween treatment and control groups at post-treatment. The results are
also consistent with several recent trials exploring purely self-guided
iCBT interventions, which have managed to obtain similar clinical out-
comes without clinician guidance (Berger et al., 2011; Furmark et al.,
2009; Titov et al., 2013; Titov et al., 2014). It is important to note that
the results of these previous trials and the current trials contrast to
meta-analytic reports (Andersson and Cuijpers, 2009; Andrews et al.,
2010; Cuijpers et al., 2009), which have indicated superior results for
trials involving regular clinician guidance over those without contact.
Unfortunately, to date, there is a relatively limited empirical basis for
understanding what factors might be leading some self-guided trials
to obtain encouraging results where others have not (Titov et al.,
2013; Andersson and Titov, 2014). However, one large recent trial indi-
cated that, regular automatic emails facilitate iCBT adherence and facil-
itate treatment outcomes in adults with comorbid anxiety and
depression (Titov et al., 2013; Titov et al., 2014). Similar automatic
emails were included in the present trials and may have contributed
to the encouraging outcomes.
Despite the outcomes, caution is neededwhen interpreting the ﬁnd-
ings of the present trials. First, being single-group feasibility open trials
without direct comparison groups, no conclusions about clinical efﬁcacy
or cost-effectiveness can be made. Further research involving direct
comparison groups is needed to draw conclusions about the efﬁcacy
of self-guided iCBT for older adults, both compared with no treatment
and clinician-guided iCBT. Second, while more than 85% of participants
met diagnostic criteria for an anxiety or affective disorder, it is impor-
tant to note that some participants did not meet diagnostic criteria
and participants were not required to report clinical level symptoms
of anxiety or depression (i.e., symptoms above clinical cut-offs) in
order to participate. Third, the samples were comprised of a young co-
hort of older adults (average age = 65.3 and 66.6; SDs = 5.33 and
3.71; range = 60 to 81) and an internet-treatment seeking sample
that consented to participate in self-guided iCBT. It is, therefore, unclear
how the results might generalize to older cohorts of older adults and
those who might present to face-to-face treatments or who want clini-
cian contact. Fourth, the present study employed the control groups of
two previous RCTs and, while attrition was low, it is unclear what effect
this may have had on the obtained results. Unfortunately, because of
this, the present study does not provide data about the acceptability
or potential rates of uptake were self-guided iCBT to be disseminatedto the public. Lastly, it is not clear from the present trials what factors
might contribute to the good clinical outcomes observed. Indeed, little
is known generally about the participant, treatment and other factors
leading to positive treatment effects in self-guided iCBT treatments
(Baumeister et al., in press) and, therefore, much more research is
needed.
Overall, the present results highlight the potential of self-guided
iCBT treatments for older adults with anxiety and depression, and the
cost and quality of life outcomes of the internet delivery of evidence-
based psychological treatment. Caution is needed in interpreting the re-
sults of the present study, however, these promising results indicate
that large replication studies involving direct comparisons with control
groups arewarranted. Further research is also needed to understand the
participant and treatment factors associated with good clinical out-
comes in self-guided iCBT treatments.
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